Trial Profile
A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Efbemalenograstim alfa (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Evive Biotech; Generon (Shanghai) Corporation
- 09 Jan 2024 Results assessing safety and efficacy of efbemalenograstim alfa for neutrophil support in breast cancer patients undergoing myelosuppressive chemotherapy published in the Supportive Care in Cancer
- 06 Jan 2015 New trial record
- 08 Dec 2014 Primary endpoint has been met (The efficacy of various single cycle doses of F-627 to measure the duration of moderate neutropenia post Chemotherapy administration as compared with the standard dosing of Neulasta) according to a Generon media release.